Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06323213
PHASE3

Efficacy and Safety Study of 610 in Patients With Severe Asthma

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

View on ClinicalTrials.gov

Summary

The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma.

Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of 610 in Chinese Adult Subjects With Severe Eosinophilic Asthma

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

480

Start Date

2024-06-24

Completion Date

2027-09

Last Updated

2026-01-07

Healthy Volunteers

No

Conditions

Interventions

DRUG

610

610 subcutaneously injection.

DRUG

Placebo

Placebo subcutaneously injection.

Locations (1)

Shanghai General Hospital

Shanghai, Shanghai Municipality, China